Baloxavir Marboxil
- Introduction
- Newest Products
Introduction
Baloxavir Marboxil
Baloxavir Marboxil was first approved for use in Japan in February 2018 and later by the FDA in October for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. Baloxavir marboxil is a cap-endonuclease inhibitor, which has a unique mechanism of action to Inhibit the proliferation of influenza virus.
Newest Products
| Image | Part # | Description | manufacturer | Stock | RFQ | |
|---|---|---|---|---|---|---|
|
|
7-(Benzyloxy)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (1370250-39-7) |
CAS: 1370250-39-7; Baloxavir manufacturer; Baloxavir intermediate; Anti-Viral
|
|
In Stock
|
|
|
|
|
(R)-7-(benzyloxy)- 3,4,12,12a-tetrahydro- 1H-[1,4]oxazino[3,4- c]pyrido[2,1-f][1,2,4]- triazine-6,8-dione (1985607-70-2) |
CAS: 1985607-70-2; Baloxavir manufacturer; Baloxavir intermediate; Anti-Viral
|
|
In Stock
|
|
|
|
|
7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol (1985607-83-7) |
CAS: 1985607-83-7; Baloxavir manufacturer; Baloxavir intermediate; Anti-Viral
|
|
In Stock
|
|
|
|
|
Baloxavir marboxil (1985606-14-1) |
CAS: 1985606-14-1;Baloxavir manufacturer; Baloxavir API; Anti-Viral
|
|
In Stock
|
|
